Immunostimulatory RNA Expression Enhances CAR T-cell Function In Vivo

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• CAR T-cell therapy is a promising cancer treatment.
• Enhancing CAR T-cell persistence and efficacy remains a challenge.
• Noncoding RNAs play critical roles in cellular functions.

Purpose of the Study:

• To investigate the potential of noncoding RNA RN7SL1 in augmenting CAR T-cell function.
• To evaluate the impact of RN7SL1-expressing CAR T cells on tumor control in vivo.
• To elucidate the mechanisms by which RN7SL1 influences endogenous anti-tumor immunity.

Main Methods:

• Generation of CAR T cells engineered to express noncoding RNA RN7SL1.
• In vivo studies using mouse models of cancer.
• Assessment of tumor growth, CAR T-cell persistence, and immune cell infiltration.
• Analysis of molecular pathways modulated by RN7SL1.

Main Results:

• CAR T cells engineered with RN7SL1 exhibited improved tumor suppression compared to control CAR T cells.
• RN7SL1 expression enhanced the persistence and cytotoxic activity of CAR T cells.
• Increased infiltration of endogenous immune cells into the tumor microenvironment was observed.
• RN7SL1 modulated key signaling pathways within CAR T cells.

Conclusions:

• Noncoding RNA RN7SL1 can be effectively utilized to enhance CAR T-cell-mediated tumor control.
• This strategy represents a novel approach to bolster endogenous anti-tumor immunity.
• RN7SL1-engineered CAR T cells hold potential for improving cancer immunotherapy outcomes.